Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?

In patients with advanced hepatocellular carcinoma who have a good performance status and Child—Turcotte—Pugh class A liver function, sorafenib represents a new standard of care.

Download full article